Induced in vivo targeted transarterial and transvenous immunostimulation in patients with unresectable pancreatic carcinoma.
On the basis of the preliminary results of this study, in vivo dual immunostimulation in patients with advanced pancreatic cancer appears to be a promising therapeutic alternative. A surgical technique is presented in which the spleen of the patient is used as the target organ for in vivo lymphokine activated killer cell generation. Additionally, applying locoregional transvenous administration of gamma-INF and IL2 in the area of the tumor, tumor infiltrating lymphocytes (TIL) area activated, thus completing the system of dual in vivo immunostimulation.
Lygidakis
N J
NJ
Department of Hepatobiliary Pancreatic Surgery, Hellenic Anticancer Institute, St. Savas Hospital, Athens, Greece.
Savanis
G
G
Toloupakis
E
E
Katsikoyiannis
N
N
Kapenanakis
A
A
Pothoulakis
J
J
Maganas
D
D
Papadimitriou
A
A
Batziotis
N
N
Zisimopoulos
A
A
D000368:Aged; D002404:Catheterization / Q000379:methods*; D002408:Catheters, Indwelling; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007371:Interferon-gamma / Q000008:administration & dosage* / Q000627:therapeutic use; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D013154:Spleen / Q000276:immunology*; D013157:Splenic Artery; D013162:Splenic Vein; D014057:Tomography, X-Ray Computed
D007376:Interleukin-2; D007371:Interferon-gamma